Login to Your Account



Phosphate Therapeutics moves PT20 toward phase III after positive phase IIb

By Michael Fitzhugh
Staff Writer

Thursday, May 7, 2015

A new experimental phosphate binder advanced by privately held Phosphate Therapeutics Ltd. to best existing treatments in moderating outsize serum phosphate levels for patients with dialysis-dependent chronic kidney disease appeared safe and effective in a pivotal phase IIb study.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription